Abstract 3194
Background
Neoadjuvant chemotherapy (NAC) has been increasingly used for gastric cancer. JCOG1302A investigated whether cT3-4/ N1-3 was a suitable criterion for NAC minimizing the contamination of pStage I. In that study, 77.2% of tumors diagnosed as cT3-4 by a combination of endoscopy and computed tomography (CT) were pT3-4. The role of endoscopic ultrasonography (EUS) or additional options in diagnosis of invasion depth was unclear.
Methods
Using data of JCOG1302A, we evaluated accuracy of endoscopic or CT diagnosis of cT3-4 to detect pT3-4, by comparing positive predictive value (PPV), negative predictive value (NPV), and kappa index (KI) between conventional endoscopy (CE) with and without EUS, CT of 5 mm and 1 mm slice, and CT with and without foaming agent (FA).
Results
Data from 1232 patients enrolled in 53 institutions were analyzed (Table). Overall, there is no remarkable difference in any comparison. More specifically, PPV and KI were slightly higher in CE alone rather than in CE combined with EUS. Although NPV was higher in 1 mm slice CT and CT with FA, PPV was higher in 5 mm slice CT and CT without FA. Table 1 Comparison of PPV, NPV, and KI between CE alone and CE combined with EUS, between 5 mm slice CT and 1 mm slice CT, and between CT without FA and CT with FA.Table: 656P
| CE alone (n = 1232) | CE combined with EUS (n = 91) | |
|---|---|---|
| PPV | 79.2% (76.2-81.9) | 73.7% (60.3-84.5) |
| NPV | 59.2% (54.3-63.9) | 58.8% (40.7-75.4) |
| KI | 0.38 (0.33-0.44) | 0.32 (0.12-0.52) |
| 5 mm slice CT (n = 1042) | 1 mm slice CT (n = 255) | |
| PPV | 77.8% (74.6-80.7) | 75.5% (68.9-81.4) |
| NPV | 62.9% (57.1-68.5) | 71.2% (57.9-82.2) |
| KI | 0.38 (0.32-0.44) | 0.39 (0.28-0.51) |
| CT without FA (n = 840) | CT with FA (n = 368) | |
| PPV | 78.6% (75.1-81.8) | 75.1% (69.5-80.1) |
| NPV | 60.9% (54.4-67.3) | 69.7% (59.7-78.5) |
| KI | 0.38 (0.31-0.44) | 0.40 (0.30-0.50) |
95%CIs are shown in brackets
Conclusions
Additional options such as EUS, 1 mm slice CT, or FA in CT may not improve diagnostic accuracy of invasion depth in resectable advanced gastric cancer.
Clinical trial identification
Legal entity responsible for the study
Japanese Clinical Oncology Group.
Funding
National Cancer Center Research and Development Fund (23-A-16, 23-A-19 and 26-A-4) from the Ministry of Health, National Cancer Center Research and Development Fund from the Ministry of Health, Labour and Welfare.
Editorial Acknowledgement
Disclosure
Y. Sato, J. Mizusawa: Grants: Ministry of Health, Labour and Welfare, Japan, Japan Agency for Medical Research and Development (AMED). K. Nakamura: Grants: Ministry of Health, Labour and Welfare, Japan, Japan Agency for Medical Research and Development (AMED); Fees: Bayer Pharma, Chugai Pharmaceutical. All other authors have declared no conflicts of interest.
Resources from the same session
4162 - ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer
Presenter: Anu Moilanen
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3747 - HER2-positive breast cancer resistance to trastuzumab is associated with metabolic switch.
Presenter: Roman Dubianski
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4688 - Combination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four Consensus Molecular Subtypes.
Presenter: Pietro Paolo Vitiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
498 - Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Presenter: Xiao Fu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3731 - Effect of the polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in Mediterranean women
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1215 - Cisplatin in NIPEC or HIPEC?
Presenter: Ivan Alvovsky
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2738 - Matrix metalloproteinase-mediated regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment
Presenter: MARIKO HIRAI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2190 - Trametinib synergizes with dexamethasone in KRAS-mutant myeloma cell lines through modulation of NDRG1 and induction of apoptosis
Presenter: Priya Sriskandarajah
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4482 - Functional inhibition of TGF-_ in colorectal cancer cells and its interaction with AXL receptor
Presenter: Davide Ciardiello
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
624 - Isoform-specific AKT Inhibition Differentially Affects Cell Functions in Pancreatic Adenocarcinoma
Presenter: Hugo Arasanz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract